All In Biotech

Drug Trial Radar · NCT07708714

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

Nov 30, 2030

Study completion Nov 30, 2032

Sponsor

Lead sponsor
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Makerere University; Indiana University; Indian Institute of Science; Mulago Hospital, Uganda
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 11 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NOHARM MTD is an extension of a previous study for children with Sickle Cell Anemia (SCA) who were enrolled in the NOHARM study. All children enrolled in NOHARM received hydroxyurea treatment at a fixed daily dose of 20 mg/kg/day. This dose was selected as a likely safe dose, but does not escalate hydroxyurea to maximum tolerated dose "MTD" as is commonly done in the US. Without this information, we cannot know whether hydroxyurea treatment at the MTD would be feasible (since it requires closer monitoring to avoid hematological toxicities), safe (since adverse events may be greater with MTD, risk of malaria may be altered by MTD, and risk of infections as a result of neutropenia could also be greater with MTD) or beneficial (MTD is associated with higher hemoglobin and fetal hemoglobin concentration).

Conditions

  • Sickle Cell Disease
  • Sickle Cell Anemia in Children

Interventions

  • hydroxycarbamideDrug

    Hydroxyurea at optimized dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite measure of organ damageTime frame: From enrollment, after 24 months and again after 48 months of study treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mulago Hospital Sickle Cell Clinic

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.